Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Klaus Wagner, MD, PhD
Neomorph, Inc
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Neo-811 Los Angeles Site
Duarte, California, United States
Recruiting - Neo-811 San Diego Site
San Diego, California, United States
Recruiting - Neo-811 Chicago Site
Zion, Illinois, United States
Recruiting - Neo-811 Grand Rapids Site
Grand Rapids, Michigan, United States
Recruiting - Neo-811 Long Island Site
Lake Success, New York, United States
Recruiting - Neo-811 Nyc Site
New York, New York, United States
Recruiting - Neo-811 South Carolina Site
Myrtle Beach, South Carolina, United States
Recruiting - Neo-811 Dallas Site
Dallas, Texas, United States
Recruiting - Neo-811 Houston Site
Houston, Texas, United States
Recruiting - Neo-811 Virginia Site
Fairfax, Virginia, United States
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 Dec 2025
- Primary completion
- 31 Jan 2027
- Completion
- 30 Sept 2027
- Last update posted
- 2 Jun 2026
- Registered enrollment
- 30
- Registry id
- NCT07300241
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.